Le Lézard
Classified in: Health
Subject: PVP

Shiny Health & Wellness Extends Private Placement


Progress Towards Building A Strong Canadian Brand

TORONTO, Nov. 6, 2023 /CNW/ - Shiny Health & Wellness Corp. (the "Company") (TSXV: SNYB) announces today that the it has received approval from the TSX Venture Exchange ("TSXV") to extend the closing of its previously announced non-brokered private placement financing of units (each, a "Unit") at a price of $0.10 per Unit (the "Offering") to December, 1, 2023. The Company closed a first tranche of the Offering on October 4, 2023 (the "First Tranche") and anticipates that the second and final tranche closing will occur on or before December 1, 2023. For more information on the Offering and the First Tranche, please see the Company's press release dated October 4, 2023.

The Company intends to use the net proceeds of the Offering for general working capital requirements, including to advance the Company's cannabis line of business performance by increasing store inventory, new store build-outs, plus acquisitions.

The closing of the Offering is subject to receipt of all necessary regulatory approvals including the TSX Venture Exchange (the "TSXV"). Finder's fees will be payable in accordance with the policies of the TSXV. The Unit Shares, Warrant Shares and any common shares of the Company that are issuable from any finder's warrants will be subject to a hold period of four months and one day following the closing date of the Offering in accordance with applicable securities laws. 

This news release does not constitute an offer to sell or a solicitation of an offer to buy any of the securities in the United States. The securities have not been and will not be registered under the United States Securities Act of 1933, as amended (the "U.S. Securities Act") or any state securities laws and may not be offered or sold within the United States or to U.S. persons unless registered under the U.S. Securities Act and applicable state securities laws or an exemption from such registration is available.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of the release.

About Shiny Health & Wellness:

Shiny Health & Wellness Corp. is on a mission to help people never settle, live fully by being a trusted source for health and wellness solutions and services. The Company operates ShinyBud Cannabis Co., a well-established brand of adult-use dispensaries in Ontario strategically located in markets less saturated with cannabis retailers. Shiny Health trades on the TSX Venture Exchange (TSXV) under the ticker symbol SNYB. For more information, please visit www.shinyhealthandwellness.com.

SOURCE Shiny Health & Wellness Corp.


These press releases may also interest you

at 22:00
Frost & Sullivan recently analyzed the hospital industry and noted that operational inefficiencies, workflow interruptions and shortage of skilled healthcare professionals are some key challenges faced by the healthcare industry. Based on its...

at 20:14
Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmune, ophthalmology...

at 19:30
The law firm of Kessler Topaz Meltzer & Check, LLP informs investors that the firm has filed a securities fraud class action lawsuit against agilon health, inc. ("agilon" or the "Company").  This action, captioned Hope v. agilon health, inc., et...

at 18:00
bioLytical Laboratories Inc. announced today the immediate availability of its INSTI® HCV Antibody Test in the Australian market.  The INSTI Hepatitis C (HCV) Antibody Test is now included in the Australian Register of Therapeutic Goods (ARTG...

at 17:20
The Phase IIa COURSE trial was a proof-of-concept study in people with moderate to very severe chronic obstructive pulmonary disease (COPD) with a broad range of blood eosinophil counts (BEC) and irrespective of emphysema, chronic bronchitis or...

at 14:15
Endeavor BioMedicines, a clinical-stage biotechnology company developing medicines with the potential to deliver transformational clinical benefits to patients with life-threatening diseases, announced results from a completed Phase 2a clinical trial...



News published on and distributed by: